The Netherlands Blocks Dr. Reddy’s Drug Shipment Bound For Brazil
This article was originally published in PharmAsia News
Executive Summary
Dutch authorities seized a shipment of drugs from Dr. Reddy's Laboratories to Brazil, the first time a shipment of a major Indian drug maker has been seized for patent infringement. The drugs in the shipment were generics worth $500,000, composed primarily of losartan for treating high blood pressure and patented in The Netherlands by DuPont of U.S. as Cozaar. India's commerce secretary called the move an act of piracy and complained to the European Commission. Many shipments of small- and medium-sized Indian makers of bulk drugs had reported previous seizures by Dutch authorities of shipments bound for other countries. Indian lawyers argue the drugs are not destined for Dutch consumers and should not be blocked if they do not violate the patent laws of India or the nation of destination. (Click here for more
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.